Why the study?
CKD carries a higher risk of cardiovascular events including PAD, and resistin is implicated in CVD processes, but its correlation with PAD in non-dialysis CKD stage 3 to 5 remains unclarified.
Is serum resistin level correlated with peripheral artery disease in patients with non-dialysis CKD stage 3 to 5?
Is serum resistin level correlated with peripheral artery disease in patients with non-dialysis CKD stage 3 to 5?
High serum resistin level is an independent predictor of peripheral artery disease in patients with non-dialysis CKD stage 3 to 5.
Answers are grounded in this paper and cite their sources.
High resistin was associated with PAD in non-dialysis CKD stages 3-5; hypothesis-generating for its added prognostic value.
Chronic kidney disease (CKD) is associated with higher risk of cardiovascular disease-related ischemic events, which includes peripheral arterial disease (PAD). PAD is a strong predictor of future cardiovascular events, which can cause significant morbidity and mortality. Resistin has been found to be involved in pathological processes leading to CVD. Therefore, we aim to investigate whether resistin level is correlated with PAD in patients with non-dialysis CKD stage 3 to 5. There were 240 CKD patients enrolled in this study. Ankle-brachial index (ABI) values were measured using the automated oscillometric method. An ABI value < 0.9 defined the low ABI group. Serum levels of human resistin were determined using a commercially available enzyme immunoassay. Thirty CKD patients (12.5%) were included in the low ABI group. Patients in the low ABI group were older and had higher resistin levels as well as higher diabetes mellitus, hypertension and habit of smoking, and lower estimated glomerular filtration rate than patients in the normal ABI group. After the adjustment for factors that were significantly associated with PAD by multivariate logistic regression analysis, age and serum resistin level were independent predictors of PAD. A high serum resistin level is an independent predictor of PAD in non-dialysis CKD stage 3 to 5.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: